Adenosine A3 receptor activation is neuroprotective against retinal neurodegeneration

Exp Eye Res. 2015 Nov:140:65-74. doi: 10.1016/j.exer.2015.08.009. Epub 2015 Aug 18.

Abstract

Death of retinal neural cells, namely retinal ganglion cells (RGCs), is a characteristic of several retinal neurodegenerative diseases. Although the role of adenosine A3 receptor (A3R) in neuroprotection is controversial, A3R activation has been reported to afford protection against several brain insults, with few studies in the retina. In vitro models (retinal neural and organotypic cultures) and animal models [ischemia-reperfusion (I-R) and partial optic nerve transection (pONT)] were used to study the neuroprotective properties of A3R activation against retinal neurodegeneration. The A3R selective agonist (2-Cl-IB-MECA, 1 μM) prevented apoptosis (TUNEL(+)-cells) induced by kainate and cyclothiazide (KA + CTZ) in retinal neural cultures (86.5 ± 7.4 and 37.2 ± 6.1 TUNEL(+)-cells/field, in KA + CTZ and KA + CTZ + 2-Cl-IB-MECA, respectively). In retinal organotypic cultures, 2-Cl-IB-MECA attenuated NMDA-induced cell death, assessed by TUNEL (17.3 ± 2.3 and 8.3 ± 1.2 TUNEL(+)-cells/mm(2) in NMDA and NMDA+2-Cl-IB-MECA, respectively) and PI incorporation (ratio DIV4/DIV2 3.3 ± 0.3 and 1.3 ± 0.1 in NMDA and NMDA+2-Cl-IB-MECA, respectively) assays. Intravitreal 2-Cl-IB-MECA administration afforded protection against I-R injury decreasing the number of TUNEL(+) cells by 72%, and increased RGC survival by 57%. Also, intravitreal administration of 2-Cl-IB-MECA inhibited apoptosis (from 449.4 ± 37.8 to 207.6 ± 48.9 annexin-V(+)-cells) and RGC loss (from 1.2 ± 0.6 to 8.1 ± 1.7 cells/mm) induced by pONT. This study demonstrates that 2-Cl-IB-MECA is neuroprotective to the retina, both in vitro and in vivo. Activation of A3R may have great potential in the management of retinal neurodegenerative diseases characterized by RGC death, as glaucoma and diabetic retinopathy, and ischemic diseases.

Keywords: A(3) adenosine receptor; Axon injury; Excitotoxicity; Ischemia-reperfusion; Neuroprotection; Retinal ganglion cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Adenosine A3 Receptor Agonists / pharmacology
  • Adenosine A3 Receptor Antagonists / pharmacology
  • Animals
  • Animals, Newborn
  • Apoptosis / drug effects
  • Cell Survival
  • Disease Models, Animal
  • Excitatory Amino Acid Agonists / toxicity
  • Fluorescent Antibody Technique, Indirect
  • In Situ Nick-End Labeling
  • Intravitreal Injections
  • Male
  • N-Methylaspartate / toxicity
  • Neuroprotection / physiology*
  • Optic Nerve Injuries / metabolism
  • Organ Culture Techniques
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A3 / metabolism*
  • Retina / drug effects
  • Retina / pathology
  • Retinal Degeneration / metabolism
  • Retinal Degeneration / prevention & control*
  • Retinal Neurons / metabolism*

Substances

  • Adenosine A3 Receptor Agonists
  • Adenosine A3 Receptor Antagonists
  • Excitatory Amino Acid Agonists
  • Receptor, Adenosine A3
  • N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
  • N-Methylaspartate
  • Adenosine
  • 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide